CXCL12 and familial pancreatic carcinoma: Although the treatment with LDE225 attenuates pancreatic cancer growth in KPC mice, LDE225 increases chemokine Cxcl12 expression, reduces CD8-positive T cells, and increases regulatory T cell (Treg) immunosuppression [36].